Giredestrant Improves Survival Outcomes in ER-Positive, HER2-Negative Early-Stage Breast Cancer
Key Clinical Takeaways
- Giredestrant significantly improved invasive disease-free survival compared with standard endocrine therapy (HR, 0.70), with higher 3-year IDFS rates and consistent benefit across disease stages.
- Trends toward improved overall survival and significantly improved distant recurrence-free interval support the clinical activity of this next-generation oral SERD.
- Giredestrant demonstrated favorable tolerability with lower treatment discontinuation rates and a safety profile comparable to standard endocrine therapy.
Aditya Bardia, MD, UCLA Health, Los Angeles, California, discusses results from the phase 3 lidERA trial evaluating giredestrant versus standard endocrine therapy for patients with ER-positive, HER2-negative early-stage breast cancer.
Giredestrant significantly improved invasive disease-free survival, showed favorable trends in overall survival and distant recurrence-free interval, and demonstrated a well-tolerated safety profile with fewer treatment discontinuations. These findings position giredestrant as a potential new standard adjuvant endocrine therapy option.
These findings were presented at the 2025 San Antonio Breast Cancer Symposium in San Antonio, Texas.
Source:
Bardia A, Schmid P, Martin M, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Presented at SABCS 2025. December 9 - 12, 2025. San Antonio, Texas. Abstract GS1-10
